In resource-rich countries, chronic hepatitis C (CHC) infection is associated with a sizeable excess mortality risk. The extent to which this is due to (1) the biological sequelae of CHC infection versus (2) a high concomitant burden of health risk behaviors (HRBs) is unclear. We used data from the 1999-2010 U.S. National Health and Nutritional Examination Surveys (NHANES), which include detailed information on HRBs and CHC infection status. We calculated the prevalence of the five major HRBs-alcohol use; cigarette smoking, physical inactivity, unhealthy diet, and illicit drug useaccording to CHC after adjusting for sociodemographic differences. Mortality status after survey interview was ascertained by linkage to the U.S. National Death Index. To assess the contribution of HRBs to the excess mortality risk, we determined the all-cause mortality rate ratio (MRR) for individuals with CHC relative to individuals without, and then calculated the attenuation in this MRR following adjustment for HRBs. This analysis included 27,468 adult participants of NHANES of which 363 tested positive for CHC. All HRBs were markedly more prevalent among individuals with CHC versus individuals without. CHC was associated with a 2.4-fold higher mortality rate after adjustment for sociodemographic factors (MRR, 2.36; 95% CI, 1.60-3.49). Subsequent adjustment for all five HRBs attenuated this ratio by 50.7% to MRR 1.67 (95% CI, 1.14-2.44). Higher levels of attenuation (69.1%) were observed among individuals aged 45-70 years, who form the target demographic for U.S. birth cohort screening. Conclusion: At least half the excess mortality risk for individuals with CHC in the United States may be attributed to HRBs rather than CHC. The remedial response to hepatitis C must not neglect action on HRBs if it is to fully resolve the high mortality problem in this population. (HEPA-TOLOGY 2018;67:97-107).
C hronic hepatitis C (CHC) infection is a major global health concern, affecting approximately 80 million people worldwide. (1) CHC is associated with considerable excess mortality in resourcerich settings. In Western Europe, North America, and Australia, all-cause mortality rates are 3.1-6.7 times higher among individuals diagnosed with hepatitis C virus (HCV) antibodies versus the general population (after adjustment for age, sex, and calendar year). (2) (3) (4) (5) (6) (7) The elevated mortality risk is most pronounced in younger age groups. For example, all-cause mortality is 9.0 times higher than the general population among infected persons in Scotland aged 20-49 years, but only 3.7 times higher among infected persons aged 50 years. (3) Understanding the factor(s) driving this excess mortality risk is a prerequisite to an effective remedial response. Currently, the extent to which the excess mortality reflects: (1) the biological sequelae of CHC infection versus (2) a high concomitant burden of health risk behaviors (HRBs) is unclear. On the one hand, CHC infection causes persistent inflammation and scarring of the liver, which, over time, can lead to liver cirrhosis (LC) and liver cancer. (8) CHC infection has also been causally linked to a wide variety of extrahepatic diseases, including diabetes, non-Hodgkin's lymphoma, and cardiovascular disease. (9) (10) (11) On the other hand, data are emerging that suggest that HRBs play an important contributory role to the impaired survival of this population. Approximately one third of CHC patients attending liver clinics self-report a history of heavy alcohol, whereas more than half report previous injecting drug use (IDU) . (12, 13) Studies examining what people diagnosed with hepatitis C die from in resourcerich settings indicate two dominant causes of death. (14) First, drug-related mortality (accounting for 18%-27% of total deaths) and, second, liver disease (accounting for 18%-24% of total mortality). Of mortality attributed to liver disease, we previously estimated that only 55%-66% is attributable to CHC in Denmark and Scotland, (15) and speculated that the residual component may reflect the consequences of excess alcohol use (which is strongly associated with LC and liver mortality in persons with CHC (13, 16, 17) ). Furthermore, although cure of CHC is associated with a reduction in mortality risk, (18, 19) mortality nevertheless remains 1.9 times higher than the general population in cured patients, with health behaviors (specifically markers of heavy alcohol use and IDU) being key mortality determinants. (20) Thus far, no study has systematically examined the collective contribution of the five major HRBs-excess alcohol use, cigarette smoking, physical inactivity, unhealthy diet, and illicit drug use (21) -to the excess mortality risk in persons with CHC. And, particularly, no study has done so in a sample representative of the CHC-infected population as a whole (i.e., most studies are confined to diagnosed individuals, thereby ignoring the appreciable proportion, typically >50%, (32) of the infected population that are unaware of their infection). Therefore, in this study, we analyzed generalpopulation data from the U.S. continuous National Health and Nutritional Examination Survey (NHANES), which is unique in including individuallevel data on: (1) baseline chronic HCV status; (2) self-reported HRBs; and (3) subsequent mortality events through to December 2011. Specific questions that we set out to address in this study were as follows. First, what is the size of the excess mortality risk in a population-based sample (i.e., inclusive of diagnosed and undiagnosed persons), after adjusting for basic sociodemographic factors? Second, what are the prevalence differences in the five major HRBs according to CHC infection status? Third, to what extent do any such prevalence differences in HRBs account for the excess mortality risk in U.S. persons with CHC infection?
Materials and Methods

BRIEF DESCRIPTION OF NHANES
The continuous National Health and Nutritional Examination Survey (NHANES) is a large, crosssectional health survey of the U.S. population. The survey was first carried out in the year 1999 and has been repeated annually ever since. The survey sample-comprising approximately 5,000 individuals per year-is selected through a complex, multistage process that ensures generalizability to the U.S. civilian noninstitutionalised household population (see a published work (23) for more details). Participation in NHANES entails completion of an initial household interview and/or a detailed health examination conducted in a bespoke mobile examination center (MEC). Data collected on survey participants include,
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inter alia, information pertaining to: socioeconomic factors; demographic factors; medical history; HRBs; and medical/physiological measurements. In addition, various laboratory tests-including tests for CHC and other blood borne viruses-are carried out on participant urine and blood specimens. (24) Although NHANES includes representation from all age groups, data on alcohol, drug-and tobacco-related HRBs are only publicly available for participants aged 20 years. The raw data used in this analysis can be found at: https://wwwn.cdc.gov/nchs/nhanes/Default.aspx.
INCLUSION CRITERIA
We included all adults (defined as aged 20 years at time of survey interview) who participated in NHANES from 1999 to 2010; and who completed the household interview, MEC examination, and dietary questionnaire components of the survey. We excluded any individuals with unknown CHC infection status and/or any individual who could not be linked to the national death index. NHANES participants from years 2011 onward were not included in this analysis because their postsurvey mortality data were not available in the latest public-use linked mortality file.
MAJOR DATA VARIABLES
We characterised survey participants with respect to: (1) sociodemographic factors; (2) current HRBs (i.e., HRBs present at the time of the survey interview); (3) former HRBs (HRBs present in the past but not at the time of survey interview); (4) CHC infection status; (5) comorbid medical conditions; and (6) mortality status through to December 31, 2011.
Data on Sociodemographic Factors
Sociodemographic factors included in this analysis were age, sex, income poverty, education, survey year, and race. Income poverty is calculated in the NHANES data sets as the ratio of each participant's household income to the poverty threshold. The poverty threshold in turn is determined from the U.S. Department of Health and Human Services poverty guidelines that are used to decide eligibility to a suite of federal welfare programmes.
Data on HRBs
Excess alcohol use, cigarette smoking, physical inactivity, unhealthy diet, and illicit drug use are regarded as the major HRBs detrimental to health. We characterized each survey participant in terms of these behaviors. A distinction was drawn throughout between current HRBs (i.e., a HRB present at the time of survey interview) and past HRBs (i.e., present in the past but not at the time of survey interview). Current excess alcohol use was defined as drinking, on average, >2 drinks/day in the 12 months preceding the survey interview. We examined three severity levels of current excess use. These were mean consumption of: (1) >2 but <4 drinks/day; (2) 4 but <5 drinks/day; and (3) 5 drinks/day, in the 12 months preceding survey examination. Participants who reported consuming "at any time in their life, five alcoholic drinks or more almost every day" were considered to be former heavy alcohol users providing their current alcohol intake was below the 5 drinks/day threshold. For all the above measures of alcohol use, 1 drink was defined as that containing 14 g of pure alcohol (equivalent to 1.75 UK units). Current drug use was defined as the use of an illicit drug at least once within the past year. We considered two types of current drug users; those who had used a needle in the last year to inject drugs and those who had not. Individuals who had not used drugs in the last year, but had done so in the past, were considered to be former drug users. Similarly, we distinguished between former drug users that had ever injected drugs with a needle from former drug users who had not. Changes to the drug-use questionnaire in 2005 meant that we could not keep the definition of noninjecting drug exactly the same for all survey participants. For 1999-2004 participants therefore, non-IDU refers to use of "cocaine or any other street drug (excluding marijuana)," whereas for 2005-2010 participants, it refers more specifically to use of "cocaine, crack cocaine, heroin or methamphetamine," Unhealthy eating was based on the amount of fruit and vegetables the participant reported consuming in the 24-hour period preceding survey examination. We used the U.S. Department of Agriculture food codes to distinguish fruits/vegetables from other foods (see Supporting Table S1 ). We defined a single portion of fruit or vegetable as that which weighs 30 or 80 g in dried or nondried forms, respectively. We defined "healthy eating" as consumption of at least 3 distinct portions of fruit/vegetable (analogous to definitions adopted in previous studies (25) ). By the same token, participants who consumed less than 3 portions of fruit/ vegetables (or consumed >53 portions, but with those portions spread out across less than 3 distinct fruits or vegetables) were considered in this analysis to have an "unhealthy" diet. Data on past/former unhealthy eating habits are not available in NHANES. Current physical inactivity was defined as the absence of regular moderate or vigorous physical activity at the time of the survey interview. As with illicit drug use, modifications to the physical activity questionnaire meant that inactivity was defined slightly differently according to survey year. For 1999-2004 participants, inactivity was defined as the absence of any moderate/vigorous activity in the 30 days preceding survey interview, whereas for 2005-2010 participants, inactivity was defined as reporting the absence of any moderate/vigorous activity "in a typical week." No data on former physical inactivity were available in NHANES. In relation to cigarette smoking, a participant was considered to be a current smoker, if at the time of their interview they reported smoking cigarettes "now" (either "every day" or on "some days"). Individuals who were not current smokers but who reported smoking more than 100 cigarettes at any point in their life were categorized as former smokers. Of note, information on cigarette smoking, alcohol consumption, physical activity, and dietary intake were elicited from participants by face-to-face interviews, conducted either at the participant's home or at the NHANES MEC. Data on illicit drug use was collected with greater anonymity through a computer-assisted, self-administered questionnaire carried out at the MEC.
Data on CHC Infection Status
NHANES participants submit a blood sample that is later tested for viral markers, including markers of CHC, hepatitis B, and human immunodeficiency virus (HIV) infection. We defined CHC infection as positivity for both HCV antibodies and HCV RNA. Individuals testing negative for HCV antibodies were considered to be without CHC. Individuals testing positive for HCV antibodies, but negative for HCV RNA, were also considered to be without CHC. Individuals with unknown CHC status (as indicated by a missing or indeterminate result for HCV antibodies, or a missing result for HCV RNA if the participant tested positive for HCV antibodies) were excluded from this analysis.
Data on Comorbid Medical Conditions
We included data on whether the following conditions had ever been diagnosed by a doctor or other health professional: heart disease; chronic obstructive pulmonary disease; cancer; and diabetes. Heart disease was defined as previous diagnosis of congestive heart failure, coronary heart disease, angina, or a past heart attack. Chronic obstructive pulmonary disease was defined as emphysema or chronic bronchitis. Obesity was defined as having a body mass index of 30 kg/m 2 . Current infection with other blood borne viruses was based on positivity for hepatitis B surface antigen protein and/or antibodies to HIV. Of note, testing for HIV antibodies were only carried out for participants aged 0-49 years at baseline, and so data are missing for a large portion of our complete sample.
Data on Subsequent Mortality Status
The vital status at December 31, 2011 of survey participants was ascertained through linkage to the 2015 public-use linked mortality file. This file is generated through probabilistic matching of NHANES participants to the U.S. National Death Index. (26) 
STATISTICAL ANALYSIS
Our analysis comprised two strands: first, assessment of the prevalence difference in HRBs according to CHC infection and, second, assessment of the contribution that these prevalence differences make to the excess mortality risk. Both analyses were carried out initially on the whole cohort and then specifically for participants aged 45-70 years at baseline. This latter subgroup analysis was intended to mirror the eligibility criteria for one-time HCV antibody testing, currently recommended for individuals in the United States born between 1945 and 1965. (27) All analyses took account of the multistage complex sampling design of NHANES. (23) Each participant was assigned the sample weight provided on the dietary questionnaire files (because this was our smallest analysis subpopulation). When combining participants from different survey cycles (i.e., years 1999-2010), we recalibrated these weights so that our final pooled sample mirrored the sociodemographic composition of the U.S. civilian noninstitutionalized population at the time of year 2000 census (see a published work (28) for further details). Variance estimates were adjusted by Taylor series linearization throughout.
Analysis 1: Prevalence of HRBS according to CHC infection status
We calculated the prevalence of current and former HRBs in participants according to CHC infection status.
Each prevalence estimate was standardized for baseline age, race, education, and sex, using a standard population derived from the age/race/education/sex distribution of survey participants with CHC infection (see Supporting  Table S1 ). In this way, for participants with CHC infection, our estimates reflect the actual observed prevalence of each HRB, whereas for participants without CHC, our estimates reflect the expected prevalence given the same sociodemographic distribution as per the CHCinfected population. Individuals missing data for a given HRB were not included in the prevalence estimate for that HRB, but were included in the prevalence estimate for other HRBs where the requisite data were not missing-as a result, each HRB prevalence estimate can be based on a slightly different denominator.
Analysis 2: Contribution of HRBS to excess mortality in persons with CHC A Poisson regression model was fitted to determine the mortality rate ratio (MRR) for CHC infection versus no CHC infection after adjustment for sociodemographic factors. This initial model is referred to as the base model. We then determined the % attenuation (i.e., the % reduction) in the base model MRR following further adjustment for: comorbid medical conditions; former HRBs; current HRBs; and former 1 current HRBs. Participants missing data for one or more covariates were included in regression models by the generation of missing indicator variables. Thus, this ensured that the base model and all further adjustment models were based on the same set of survey participants.
Results
DESCRIPTION OF FINAL SAMPLE
A total of 29,130 participants met our inclusion criteria, 1,631 (5.6%) were then excluded on account of missing CHC infection status, and a further 31 (0.1%) participants were discounted because their mortality status at December 2011 could not be ascertained. The final sample therefore was 27,468 individuals, of which 363 (weighted prevalence, 1.2%) had CHC infection at baseline. The complete breakdown of the cohort in terms of sociodemographic factors, comorbid medical conditions, and HRBs is shown in Supporting Table  S2 . Relative to those without CHC, participants with CHC were more likely to be: older; male; be nonHispanic black; living below the poverty threshold; and not have more than a high school education (see Table 1 ). At the end of follow-up, 6.2 years on average after the baseline survey interview, 2,599 (9.5%) participants in our sample had died (43 of these deaths were among persons with CHC infection; see Supporting Table S3 ). Crude mortality rates by CHC status are shown in Supporting Table S4 . In our final sample, the proportion of participants missing data for a given covariate was low at 0%-6% (see Supporting Table S2 ). The two exceptions to this were data on illicit drug use (which was missing for 25.5% of participants) and data on HIV infection status (missing for 38.8% of participants).
ANALYSIS 1: PREVALENCE OF HRBs ACCORDING TO CHC INFECTION STATUS
HRBs were more prevalent among individuals with CHC infection versus individuals without. This applied particularly to current HRBs. Current excess alcohol use was 2.3 times more prevalent (18.7% for CHC infected vs. 8.3% for CHC uninfected; P < 0.001). Current cigarette smoking was 2.3 times as prevalent (63.8% for CHC infected vs. 28.2% for CHC uninfected; P < 0.001). Current IDU was 93 times as prevalent (9.3% for CHC infected vs. 0.1% for CHC uninfected; P 5 0.001). Current non-IDU was 3.4 times as prevalent (16.2% for CHC infected vs. 4.7% for CHC uninfected; P < 0.001). Comparable differences were observed in our subgroup analysis of patients aged 45-70 years at baseline (see Table 2 ). The prevalence difference (i.e., the absolute difference in prevalence between participants with CHC vs. participants without) is shown for each HRB in descending order in Fig. 1 .
ANALYSIS 2: CONTRIBUTION OF HRBs TO EXCESS MORTALITY IN PERSONS WITH CHC
In our final sample of 27,468 survey participants, the MRR comparing individuals with CHC infection to individuals without, after adjustment for sociodemographic factors alone, was 2.36 (95% confidence interval Results are presented for all survey participants and for survey participants aged 45-70 years at baseline. *Standardized to reflect the same % prevalence expected given the same age at interview/race/education/gender distribution as for CHC infected participants -see Supporting In our subgroup analysis of individuals aged 45-70 years at baseline (N 5 10,810), the sociodemographicadjusted MRR was smaller than for the full cohort at 1.68 (95% CI, 0.89-3.20). Attenuation attributed to HRB adjustment was even more pronounced in this subgroup versus the full cohort. For instance, adjustment for current HRBs attenuated the MRR by 69.6%, whereas adjustment for current 1 former HRBs attenuated the MRR by 69.1% (see Table 3 ).
Discussion
MAIN FINDINGS
The existence of a substantial excess mortality risk for individuals with CHC infection in resource-rich countries (2-7) is a major clinical and public health concern. Although the detrimental effect of CHC itself is the most obvious explanation for this phenomenon, other factors may be contributing, too. In this study, we used unique data from a large U.S. community survey to examine the extent to which HRBs contribute to excess mortality in this population. As expected, we observed a considerable excess mortality risk for individuals with CHC infection after adjusting for sociodemographic factors. Specifically, the all-cause mortality rate for individuals with CHC was 2.4 times higher than for individuals without CHC (an excess which, if extrapolated to the U.S. population as a whole, equates to 39,000 surplus CHC deaths every year; see Supporting Appendix A). However, the key finding from this study is that this excess mortality risk attenuated considerably-by 50.7%-following subsequent adjustment for all HRBs. This suggests that although CHC is a well-known cause of hepatic and extrahepatic disease, half the mortality excess may actually reflect the consequences of HRBs rather than CHC itself. The impact of ameliorating HRBs in the CHCinfected population could therefore be considerable, and so it is striking that the evidence base on this topic is so thin. In a recent systematic review, Doyle et al. could identify only two randomized, controlled trials (RCTs) for an alcohol reduction intervention in patients with HCV. (29) In the same vein, we were unable to identify a single RCT evaluating a smoking cessation intervention for patients with HCV in our own brief literature search (see Supporting Appendix B). Overall, this study cautions that-advancements in antiviral therapy (30) asidea sizeable excess mortality risk is likely to persist for individuals with past/present CHC unless more attention is paid to tackling coexisting HRBs.
U.S. BIRTH COHORT SCREENING
In 2012, the Centers for Disease Control and Prevention (CDC) recommended that all U.S. individuals born between 1945 and 1965 receive one-time testing for HCV. (27) When we restricted our analysis to individuals aged 45-70 years (i.e., to roughly mirror the age range that birth cohort screening will in practice be applied to) we observed even higher levels of attenuation to that of the full cohort (69.1%), and similarly observed that most of the attenuation was driven by adjustment for current HRBs (particularly cigarette smoking). Although this result does not undermine birth cohort screening as such (i.e., whereas the MRR for this subgroup was not statistically significant, this probably reflects a lack of statistical power as opposed to a real noneffect of CHC on mortality), they do persuade that addressing HRBs should form a strong component of this intervention. At present, this is arguably not the case. Although the CDC does recommend that those testing positive for HCV be advised to decrease their alcohol consumption, they concede that the evidence base on how to actually deliver this advice is limited. (27) Further U.S. birth cohort screening omits guidance on counseling for other relevant HRBs (notably for cigarette smoking, which led to the strongest attenuation in the excess mortality risk for this population).
LIMITATIONS OF STUDY
There are several limitations of this study. We had no data on individuals with CHC infection clearing infection by antiviral therapy during follow-up. In theory, this could bias the size of the excess mortality risk toward the null. However, the rate of clearing CHC through antiviral treatment was minimal in the United States during the time period of this analysis-only around 1.4 sustained virological responses per year for every 100 infected persons (see Supporting Appendix C)-and so is unlikely to affect our conclusions. A second limitation relates to selection bias; survey participants who completed both the mobile examination and dietary components of this survey (i.e., the inclusion criteria of this study) may differ from those who did not. However, the survey weights assigned to survey participants are calibrated to adjust for differential response by sociodemographic factors, (31) and, in any case, nonresponse rates were reasonably low (i.e., 67% of those invited to participate in NHANES fulfilled the inclusion criteria of this study; see Supporting Fig.  S1 ). Third, NHANES is a survey of the civilian noninstitutionalized population and therefore excludes individuals who are homeless or in prison (two subpopulation where the prevalence of HCV is high (32, 33) ). Thus, although NHANES may not perfectly represent the general CHC infected population in the United States, it will provide a far more representative sample than the alternative of diagnosis/treatment cohorts. Fourth, some individuals in our cohort were missing data for one or more HRBs. Mostly, the proportion with missing data was low (<5%), but it was more common in relation to data on illicit drug use (where 25.5% of our final sample were missing data on this HRB). The high frequency of missing drug-use data was due to the NHANES survey protocol rather than individuals choosing to not respond to the requisite questions. were not posed to participants aged 60 and 70 years, respectively. It is possible that the age/survey year patterning of this missing data could have caused bias with respect to the association between illicit drug use and mortality risk. Fifth, this study would ideally have stratified % attenuation across a number of sociodemographically defined subgroups. However, low statistical power (stemming from only 43 deaths in the CHC infected population overall) precluded us from doing this in a robust way. For a similar reason, we were not able to stratify % attenuation by cause of death. That said, we did examine the categories of death contributing most to the excess mortality in CHC participants (see Supporting Appendix D), and found that 30% of the excess was attributed to deaths from accidents (which, prima facie, is consistent with a strong HRB contribution). However, this supplementary analysis is again limited by the small number of deaths and the broad cause-of-death categories themselves (the selection of which we had no control over). A final limitation is that the HRB data were measured at a single cross-sectional time point. Longitudinal data would have been superior in that it would have allowed us to take account of any changes in HRBs occurring over the course of follow-up. Previous work has suggested that analyzing HRBs on the basis of cross-sectional data, as opposed to longitudinal data, will understate contribution of HRBs on mortalityparticularly with regard to the contribution of poor diet and physical inactivity. (34) 
CONSISTENCY WITH PREVIOUS NHANES RESEARCH
Our analysis is consistent with previous studies of NHANES data, establishing: (1) a heightened prevalence of current alcohol use among persons with hepatitis C (35) and (2) that alcohol use is an independent predictor of mortality among persons with hepatitis C. (36) More notably, however, these findings are consistent with a study by El-Kamary et al., (37) which also indicated substantial attenuation in the mortality excess following adjustment for a broad range of cofactors. However, there were some important limitations of this study. First, it was based on historical NHANES III data (the interviews for which were carried 20-25 years ago between 1988 and 1994); as such the data may not be representative of individuals living with CHC infection today. Second, their analysis did not include detailed data on HRBs such as dietary intake, exercise, past alcohol use, and IDU history.
The absence of these data precludes a comprehensive assessment of the total impact of HRBs. Third, ElKamary et al. asked a fundamentally different question of the data to that of this study-namely, Does HCV remain independently associated with higher mortality even after adjusting for all relevant confounders? As such, they did not report attenuation following adjustment for HRBs as we have done here.
In conclusion, individuals with CHC infection in the United States exhibit a considerable excess mortality risk. Yet, approximately half of this excess may reflect high levels of HRBs, as opposed to the effects of CHC infection itself. This study therefore highlights the importance of a public-health response to hepatitis C that includes action on HRBs as well as access to antiviral therapy.
